<DOC>
	<DOCNO>NCT00004065</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : This phase I trial study side effect best dose 17-N-allylamino-17-demethoxygeldanamycin treating patient refractory advanced solid tumor hematologic cancer .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Refractory Advanced Solid Tumors Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) patient refractory advanced solid tumor hematologic malignancy . - Evaluate effect drug expression signal protein present individual patient 's cancer start treatment , possible , post treatment . OUTLINE : This two-phase , dose-escalation , multicenter study . Patients stratify accord disease ( chronic myelogenous leukemia [ CML ] Philadelphia chromosome [ Ph ] + acute lymphoblastic leukemia [ ALL ] v solid tumor ) . Patients receive 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) IV 60-90 minute twice weekly . Courses repeat every 12 week absence disease progression ( least 2 course CML Ph+ ALL patient ) unacceptable toxicity . - Accelerated phase : Single patient receive escalate dose level 17-AAG one patient experience first course grade 3 great toxicity two different patient experience grade 2 toxicity course . - Standard phase : Cohorts 3-6 patient stratum receive escalating dose 17-AAG maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : Approximately 51 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Histologically confirm advanced primary malignant solid tumor refractory standard therapy curative standard therapy exist Progressive disease evidence 1 following : Nonprostate cancer ( include , limited , breast , ovary , head neck , nonsmall cell lung , bladder , kidney , colon , stomach , malignant melanoma ) Development new lesion increase exist lesion No increase biochemical marker ( e.g. , carcinoembryonic antigen , CA153 , increase symptom ) sole measure disease Prostate cancer ( androgen independent ) meeting follow criterion : Progressing metastatic disease bone scan , CT scan , MRI Metastatic disease rise prostatespecific antigen ( PSA ) value meet 1 follow criterion : At least 3 rise PSA value obtain least 1 week apart = 2 rise value 1 month apart least 25 % increase range value Serum testosterone less 30 ng/mL Castrate status maintain medical therapy orchiectomy perform Progressive disease must evident antiandrogen therapy receive prior study entry Registered protocol MSKCC9040 Cytologically confirm chronic , accelerate , blastic phase chronic myelogenous leukemia ( CML ) Philadelphia chromosome ( Ph ) positive acute lymphoblastic leukemia ( ALL ) refractory standard therapy curative therapy exist Progressive disease evidence 1 following : Accelerated blastic phase disease responsive standard therapy loss hematologic response imatinib mesylate remain chronic phase CML Relapsed refractory treatment standard chemotherapy imatinib mesylate Phpositive ALL No active CNS epidural tumor Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Not specify Menopausal status : Not specify Performance status : Karnofsky 70100 % Life expectancy : At least 6 month Hematopoietic : WBC great 3,500/mm^3 Platelet count great 100,000/mm^3 No restriction base peripheral blood count CML Phpositive ALL Hepatic : Bilirubin great 1.2 time upper limit normal ( ULN ) AST le 1.5 time ULN Prothrombin time normal Renal : Creatinine great 1.5 time ULN OR Creatinine clearance great 60 mL/min Cardiovascular : No myocardial infarction within past 6 month Ejection fraction great 45 % radionuclide cardiac angiography No ventricular aneurysm abnormal wall motion No reversible defect thallium stress test follow condition present : Ejection fraction le 45 % radionuclide angiocardiography Worrisome nonexclusive cardiovascular history Abnormal echocardiogram Patients follow history clinical finding require additional diagnostic testing : Significant Q wave ( great 3 mm great onethird height QRS complex ) ST elevation depression great 2 mm attributable hypertension strain Absence regular sinus rhythm Bundle branch block Requirement diuretic reason hypertension digoxin reason atrial fibrillation Prior mild moderate congestive heart failure No New York Heart Association class III IV heart disease No angina pectoris No uncontrolled hypertension intermittent claudication No severe debilitate valvular disease Pulmonary : No severe debilitate pulmonary disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection require IV antibiotic No symptomatic peripheral neuropathy grade 2 high No severe medical condition would increase risk toxicity No allergy egg egg product PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy ( include interferon CML ) recover Chemotherapy : At least 4 week since prior chemotherapy ( 3 day hydroxyurea CML ALL ) recover No concurrent chemotherapy Endocrine therapy : See Disease Characteristics At least 4 week since prior endocrine therapy recover Radiotherapy : At least 4 week since prior radiotherapy recover Concurrent radiotherapy localize disease site use evaluate antitumor response allow No concurrent radiotherapy measurable lesion Surgery : See Disease Characteristics Prior orchiectomy allow No concurrent surgery Other : At least 3 day since prior imatinib mesylate CML ALL At least 4 week since prior investigational anticancer drug recover At least 4 week since prior palliative treatment metastatic disease No concurrent ketoconazole , warfarin , verapamil , miconazole , erythromycin No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>untreated metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>ovarian stromal cancer</keyword>
	<keyword>stage III ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III basal cell carcinoma lip</keyword>
	<keyword>stage III mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage III adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV basal cell carcinoma lip</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage IV adenoid cystic carcinoma oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent basal cell carcinoma lip</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>recurrent adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage III verrucous carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage III invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>stage III midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>stage III esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>borderline ovarian surface epithelial-stromal tumor</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>stage III verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>stage III salivary gland cancer</keyword>
</DOC>